ReviewFrontiers in pharmacology2025
Factors that influence the Na/K-ATPase signaling and function.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Role of an Angiotensin II Type-1 Receptor (ATBiological trace element research · 2026Article
- Mitochondrial Pyruvate Metabolism Controls Alveolar Stem Cell Fate and Inflammatory Balance.Inflammation · 2026Article
- Pathophysiological Roles of Two Intracellular P-Type ATPases: The Cancer-Associated NaInternational journal of molecular sciences · 2026Review
- Direct energy consumption by inhibitory GABAFrontiers in neuroscience · 2026Article
- Integrative Transcriptomic and Single-Cell Analyses Identify ATP1A1 as a Prognostic and Immune-Associated Factor in Esophageal Cancer.International journal of genomics · 2026Article
- Na,K-ATPase mediated and cardiotonic induced signaling in health and disease.Frontiers in physiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transmembrane Na/K-ATPase is located in the plasma membrane of all mammalian cells. It utilizes energy from ATP hydrolysis to execute its pumping function and interacts with other proteins and/or kinase molecules to execute its signaling function. Digoxin, one of the earliest identified cardiotonic steroids (CTS) that specifically binds to the Na/K-ATPase, has been widely prescribed to manage patients with cardiovascular disease (CVD) and heart failure (HF) for over 200 years. Elevated plasma levels of CTS have been observed in patients with hypertension, chronic kidney disease (CKD), CVD, and congestive HF. After extensive research efforts spanning decades, there remain unresolved disagreements regarding the various mechanisms underlying the Na/K-ATPase signaling functions. This article examines the known and controversial mechanisms that initiate the Na/K-ATPase signaling functions and their related regulatory mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.